IDT posts record revenue, profit and dividends
17 August, 2005 by Ruth BeranPharmaceutical manufacturing and drug development company Institute of Drug Technology Australia (ASX:IDT) has reported an operating profit after tax of AUD$4.5 million for the year ended June 30, representing an increase of 5 per cent over the previous year.
Resonance to provide FerriScan to US research institutes
17 August, 2005 by Helen SchullerResonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT) and formerly known as Inner Vision Biometrics, has agreed to provide its FerriScan diagnostic test to the New England Research Institutes (NERI) for use in its clinical studies.
Boost for medical research in Queensland
17 August, 2005 by Helen SchullerMedical research in Queensland has won a jackpot, with unclaimed first division lotto prizes to be transformed into grants for research and equipment.
Why biotech companies don't work
17 August, 2005 by Iain ScottAustralian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive.
Merck exec calls for biotech critical mass
15 August, 2005 by Ruth BeranThe oft-repeated cliche that Australia 'punches above its weight' in biotechnology is little more than a security blanket, and needs to be replaced with some real muscle, Merck Sharp & Dohme's external licensing coordinator, Graham Macdonald, told a meeting on Friday.
EG Capital tips market upswing
12 August, 2005 by Helen SchullerIn the wake of its annual Australian Biotechnology Expo, held earlier this week in Sydney, EG Capital executive director Alison Coutts is optimistic that the Australian biotech sector is on the way back up.
Dental expert wins $50,000 Victoria Prize
12 August, 2005 by Ruth BeranDental scientist Prof Eric Reynolds has won the $50,000 Victoria Prize.
Failed Allergan agreement hits Peplin's bottom line
12 August, 2005 by Ruth BeranBrisbane-based cancer therapeutic developer Peplin's (ASX:PEP) revenues dropped to AUD$3.4 million in the 2004/05 financial year, down substantially from $6.3 million in the previous year, due to the termination in October 2004 of a collaboration and license agreement with US company Allergan for the company's topical skin cancer drug PEP005.
Bone Medical's level one ADR program granted
08 August, 2005 by Ruth BeranBone Medical (ASX:BNE) has received approval for a level one American Depository Receipt (ADR) program with receipts tradable in the over-the-counter market under the code BMEDY.
Firestone: Why I left Polartechnics, and why I would return
05 August, 2005 by Ruth BeranMedico and property investor Richard Opara resigned as interim chairman of Polartechnics (ASX:PLT) on June 8. The next day, US biotech executive Len Firestone stepped down as a director.
Starphama receives Frost & Sullivan leadership award
04 August, 2005 by Ruth BeranMelbourne drug developer Starpharma (ASX:SPL) has received the 2005 Frost & Sullivan Growth Strategy Leadership Award for the company's development of VivaGel and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
In brief: SciGen, Cryptome, Circadian, ChemGenex, Synchrotron
04 August, 2005 by Ruth BeranSciGen (ASX:SIE) executive vice-chairman and founder Saul Mashaal has been reappointed as CEO, a position he held until September 2001 when executive management of the company was transferred to Australia.
Victorian medical research institutes net $26m in state grants
04 August, 2005 by Ruth BeranThe Victorian government has pledged $26.6 million in infrastructure funding to 17 independent medical research institutes in the state.
Geelong biotech cluster receives $50,000 grant
04 August, 2005 by Ruth BeranThe Geelong Region Biotechnology Cluster Project has received a $50,000 Regional Innovation Clusters Program grant from the Victorian government to support its growth.
Biotech summit highlights sector's strong voice
02 August, 2005 by Helen SchullerPartnering, collaboration and communication were keenly discussed at the 3rd Australian Biotechnology Summit, held in Sydney last week. Australian of the Year and Clinical Cell Culture (C3) co-founder Fiona Wood led the charge, calling for a solution driven biotech industry.
